论文部分内容阅读
目的 探讨葛根素治疗妊娠期高血压疾病患者的母婴结局和血浆中一氧化氮 (NO)、血栓素B2(TXB2)、内皮素(ET)、6 酮 前列腺素F1α(6-Keto-PGF1α)的变化。方法 2001年 1月至 2004年 6月广东省妇幼保健院用葛根素(A组)和硫酸镁(B组)分别治疗 50例重度子疒间前期的患者,观察两组平均动脉压、尿蛋白、胎心率异常、新生儿窒息和产后出血、羊水混浊、新生儿出生体重等情况以及治疗前后血浆NO、TXB2、ET、6 Keto PGF1α的变化情况。结果 A组治疗前后平均动脉压分别为 ( 125.5±13.3 )mmHg( 1mmHg=0 133kPa)和(103.0±15.4)mmHg,血压有显著性下降 (P<0.05 ),B组治疗前后平均动脉压为 ( 123.0±12.3 )mmHg和(119.0±13 7)mmHg,差异无显著性(P>0.05),两组治疗前后 24h尿蛋白分别为A组 (3 91±0.46)g和 (1.53±0 61)g;B组(3.89±0.39)g和(1.50±0.35)g,两组治疗前后均有显著差异性 (P<0.05)。两组血浆细胞因子治疗前后均有显著差异性(P<0.05)。B组胎心异常率为 22%,明显高于A组(P<0.05)。结论 葛根素治疗妊娠期高血压疾病时能有效降低平均动脉压,改善母血中NO、TXB2、ET、6-Keto-PGF1α的水平,对治疗有积极的作用。
Objective To investigate the effect of puerarin on maternal and neonatal outcomes and plasma levels of nitric oxide (NO), thromboxane B2 (TXB2), endothelin (ET) and 6-Keto-PGF1α in patients with gestational hypertension. The change. Methods From January 2001 to June 2004, Guangdong Provincial Maternal and Child Health Hospital were treated with puerarin (group A) and magnesium sulfate (group B), respectively. Fifty patients with severe preeclampsia were observed. The mean arterial pressure, urinary protein , Fetal heart rate abnormalities, neonatal asphyxia and postpartum hemorrhage, amniotic fluid turbidity, newborn birth weight and so on, as well as the changes of plasma NO, TXB2, ET, 6 Keto PGF1α before and after treatment. Results Before and after treatment, the mean arterial pressure in group A was (125.5 ± 13.3) mmHg (1mmHg = 0,133kPa) and (103.0 ± 15.4) mmHg, respectively, and the blood pressure was significantly lower (P < 123.0 ± 12.3) mmHg and (119.0 ± 13.7) mmHg respectively, there was no significant difference between the two groups (P> 0.05) ; B group (3.89 ± 0.39) g and (1.50 ± 0.35) g, both groups had significant difference before and after treatment (P <0.05). Plasma cytokines in both groups before and after treatment were significantly different (P <0.05). The abnormal rate of fetal heart rate in group B was 22%, which was significantly higher than that in group A (P <0.05). Conclusion Puerarin treatment of hypertensive disorders of pregnancy can effectively reduce the mean arterial pressure, improve the level of NO, TXB2, ET, 6-Keto-PGF1α in maternal blood, and have a positive effect on the treatment.